Last updated: September 2, 2026
Daclatasvir dihydrochloride has moved from a premium branded hepatitis C product to a low-cost, predominantly generic medicine. Bristol-Myers Squibb’s Daklinza franchise generated substantial early revenue, but sales declined as direct-acting antiviral competition shifted toward simpler, pan-genotypic regimens, shorter treatment courses, lower prices and combination products controlled by competitors. The commercial value of daclatasvir now rests mainly in public-health procurement and generic supply, particularly in countries where access programs and national treatment guidelines continue to use the drug.
What is daclatasvir dihydrochloride and how is it used?
Daclatasvir dihydrochloride is an orally administered hepatitis C virus NS5A replication-complex inhibitor. It was developed by Bristol-Myers Squibb and commercialized under the brand name Daklinza.
| Attribute |
Daclatasvir dihydrochloride |
| Drug class |
HCV NS5A inhibitor |
| Originator |
Bristol-Myers Squibb |
| Brand |
Daklinza |
| Dosage form |
Film-coated oral tablets |
| Common strengths |
30 mg and 60 mg |
| Primary use |
Chronic hepatitis C infection |
| Initial FDA approval |
July 2015 |
| Typical combination |
Sofosbuvir, with or without ribavirin depending on regimen |
| Small molecule or biologic |
Small molecule |
| Biosimilar pathway |
Not applicable |
| Main commercial issue |
Loss of branded relevance after pan-genotypic regimen adoption |
Daclatasvir is not generally used as monotherapy. Its clinical and commercial value depends on combination treatment, especially with sofosbuvir. The drug initially had strategic importance for genotype 3 hepatitis C, a population with fewer effective treatment options when Daklinza entered the market.
When did daclatasvir lose commercial exclusivity?
Daclatasvir lost practical branded exclusivity through a combination of patent expiry, voluntary licensing, generic competition and market substitution.
The U.S. product received five-year new chemical entity exclusivity under the Hatch-Waxman framework. That period began with FDA approval in 2015 and generally extended into 2020. U.S. market protection was also affected by the commercial withdrawal of Daklinza from the U.S. market.
The principal commercial erosion occurred before patent expiry became the only relevant issue. Competitors including Gilead Sciences’ Epclusa and AbbVie’s Mavyret offered pan-genotypic treatment with broader genotype coverage and simpler positioning. As a result, daclatasvir’s addressable market narrowed even while it remained clinically useful.
Daclatasvir exclusivity timeline
| Date |
Event |
Commercial effect |
| 2006-2008 |
Core daclatasvir patent families filed internationally |
Established originator protection |
| 2014 |
European authorization for Daklinza |
Expanded launch markets |
| July 2015 |
FDA approval for use with sofosbuvir |
Opened the U.S. market |
| 2015-2017 |
Peak branded HCV competition |
High initial pricing and rapid uptake |
| 2016-2017 |
MPP licensing and generic-access arrangements |
Reduced long-term exclusivity in eligible markets |
| 2016 onward |
Epclusa and Mavyret gained market share |
Reduced demand for daclatasvir-based regimens |
| 2019-2020 |
U.S. commercial discontinuation and end of key regulatory exclusivity periods |
Removed the major branded-market opportunity |
| 2020 onward |
Generic and public-health supply became dominant |
Shifted value from innovation pricing to volume procurement |
Patent expiry dates vary by country, patent family, patent-term adjustment and applicable supplementary protection certificate. The commercial assessment is clearer than the legal endpoint: daclatasvir is no longer a meaningful branded growth asset in the United States or major European markets.
What patents protect daclatasvir dihydrochloride?
Daclatasvir was protected by compound, process, formulation and use-related patent families. The core protection covered substituted biphenyl compounds and related HCV NS5A inhibitors. Other filings addressed pharmaceutical compositions, salt forms, crystalline forms, manufacturing processes and treatment combinations.
Patent protection was geographically fragmented. The strongest commercial protection applied in major high-income markets where branded HCV products commanded premium prices. In lower-income and middle-income markets, voluntary licensing and public-health exceptions allowed earlier generic entry.
What formulation patents protect daclatasvir?
The commercial tablet contains daclatasvir dihydrochloride with excipients designed for oral delivery and stability. Formulation patents can protect:
- The dihydrochloride salt.
- Specific crystalline or solid-state forms.
- Tablet compositions.
- Dissolution and stability characteristics.
- Manufacturing processes for the active pharmaceutical ingredient.
- Fixed-dose or co-packaged treatment approaches.
Formulation protection has limited residual value because generic manufacturers can often design around a particular tablet composition while preserving the same active ingredient and strength. For daclatasvir, the core compound and regulatory substitution dynamics mattered more than a single formulation patent.
What method-of-use patents cover daclatasvir?
Method-of-use claims may cover treatment of hepatitis C by genotype, treatment duration, combination with sofosbuvir, use with ribavirin, or treatment in patients with prior treatment failure or cirrhosis.
These claims had commercial value during the early launch period, particularly for genotype 3. Their value declined as treatment guidelines shifted toward pan-genotypic regimens and as clinical practice increasingly favored Epclusa, Mavyret and other combinations with broader labels.
What is the FDA regulatory status of daclatasvir?
FDA approved Daklinza in July 2015 for use in combination with sofosbuvir for chronic HCV genotype 1 or 3 infection, with treatment duration and ribavirin use depending on patient characteristics and genotype. The approval was clinically important because genotype 3 patients historically had fewer highly effective treatment options.
The product was later discontinued in the United States for commercial reasons. The discontinuation did not represent a safety-driven withdrawal of the active ingredient. Daclatasvir remains approved or registered in various non-U.S. jurisdictions, although local regulatory status differs by country.
The FDA pathway creates no biosimilar exposure because daclatasvir is a chemically synthesized small molecule. Competition occurs through abbreviated new drug applications, national generic procedures, WHO prequalification and local registration systems.
What is the Orange Book status of Daklinza?
Daklinza was listed in FDA product databases as an approved prescription tablet. Its commercial significance in the Orange Book declined after U.S. discontinuation and the end of the principal regulatory exclusivity period.
Orange Book-listed patents for small-molecule products can support Paragraph IV litigation if a generic applicant asserts that the listed patents are invalid, unenforceable or not infringed. Daclatasvir’s litigation exposure was limited compared with high-revenue HCV products such as sofosbuvir and ledipasvir combinations.
The practical Orange Book conclusion is that Daklinza no longer presents a material U.S. launch-barrier opportunity for the originator. The U.S. market has already shifted away from the product, and the key commercial question is generic availability rather than preservation of branded pricing.
Which companies challenged or competed with daclatasvir?
Daclatasvir faced two types of competition: direct regimen competition and therapeutic substitution.
| Company |
Product or strategy |
Effect on daclatasvir |
| Gilead Sciences |
Sovaldi, Harvoni and Epclusa |
Established dominant sofosbuvir-based treatment platforms |
| AbbVie |
Viekira Pak and Mavyret |
Increased competitive pressure, particularly with shorter and simpler regimens |
| Merck & Co. |
Zepatier |
Added another branded direct-acting antiviral option |
| Generic manufacturers |
Daclatasvir tablets and combination supply |
Reduced prices in licensed and eligible markets |
| Public-health purchasers |
Tender-based procurement |
Shifted competition toward cost, volume and supply reliability |
Gilead’s Epclusa was the most important strategic competitor because it offered pan-genotypic coverage and reduced the need to select therapy by genotype. Mavyret added further pressure with broad coverage, an eight-week treatment option for many patients and competitive pricing.
How did daclatasvir revenue change over time?
Bristol-Myers Squibb’s HCV revenue trajectory followed the broader industry pattern: rapid growth after launch, a short period of high commercial value and then sharp decline.
Daklinza sales were strongest during the initial direct-acting antiviral expansion, when treatment demand was high and payers had not yet fully normalized price competition. The product’s value was supported by its role in combination with sofosbuvir and its relevance for genotype 3.
Revenue then declined for four structural reasons:
- Pan-genotypic products reduced the need for genotype-specific treatment selection.
- Competitor regimens offered stronger convenience and broader labels.
- HCV treatment pricing fell as payers negotiated large discounts and public-health procurement expanded.
- Generic and licensed daclatasvir supply compressed price in lower-income markets.
Bristol-Myers Squibb did not establish daclatasvir as a durable standalone franchise comparable to Gilead’s sofosbuvir platform. Its economic contribution became immaterial relative to the company’s oncology, immunology and cardiovascular portfolios.
Financial trajectory
| Phase |
Approximate period |
Financial profile |
| Launch |
2014-2015 |
Rapid adoption and premium pricing |
| Expansion |
2015-2016 |
Strong demand in the branded HCV market |
| Compression |
2016-2018 |
Revenue decline from pan-genotypic competition and price concessions |
| Commercial withdrawal |
2019-2020 |
U.S. branded opportunity effectively ended |
| Generic/public-health phase |
2020 onward |
Low unit prices, procurement-driven volume and limited originator revenue |
Bristol-Myers Squibb’s reported financial statements should be used for audited product-level figures in any transaction or valuation model. Daclatasvir revenue is not a current growth indicator for the company and should not be valued using launch-period HCV multiples.
What generic entry risks exist for daclatasvir?
Generic entry risk is high. The active ingredient is a small molecule with established manufacturing knowledge, substantial clinical history and no biosimilar complexity. The main barriers are regulatory registration, quality control, supply qualification and access to relevant markets, not clinical uncertainty.
Generic manufacturers can compete through:
- Standard 30 mg and 60 mg tablets.
- Daclatasvir-sofosbuvir co-packaged regimens.
- National registration in markets outside the originator’s principal patent territory.
- WHO-supported procurement channels.
- Voluntary-license territories.
- Local manufacturing and government tender contracts.
A generic launch in a high-income market would still require review of any surviving formulation, process or use patents. In most low- and middle-income markets, however, the primary commercial barriers are tender access, quality certification and demand forecasting.
How strong is the daclatasvir patent estate?
The patent estate was strong during the first years after discovery but is weak as a current commercial moat.
| Factor |
Assessment |
| Core compound protection |
Historically strong; now largely exhausted or commercially irrelevant in major markets |
| Formulation protection |
Moderate but design-around risk is high |
| Method-of-use protection |
Narrowing value as treatment guidelines evolve |
| Manufacturing protection |
Relevant to process efficiency and quality, but generally avoidable |
| Geographic coverage |
Broad historical filing footprint, uneven current force |
| Litigation leverage |
Limited current value due market substitution |
| Generic defense |
Weak in mature markets |
| Residual value |
Public-health supply, licensing and selected emerging markets |
Daclatasvir’s main barrier is no longer patent exclusion. It is commercial positioning. A generic that offers lower price and reliable quality can capture demand where national guidelines still include daclatasvir.
What licensing deals affected daclatasvir access?
Bristol-Myers Squibb entered licensing arrangements that expanded access to daclatasvir in lower-income and middle-income markets. The Medicines Patent Pool announced a licensing agreement with Bristol-Myers Squibb covering daclatasvir in 2017. The arrangement enabled sublicensing to qualified generic manufacturers for specified countries and supported broader access to HCV treatment.
The licensing model changed the market in three ways:
- It accelerated generic entry in covered territories.
- It reduced the originator’s ability to maintain premium pricing.
- It converted patent rights into royalty and access arrangements rather than direct product sales.
Licensing had limited effect on the U.S. and major European branded markets but materially affected the long-term global volume strategy.
What is the global competitive landscape for daclatasvir?
The global HCV market now favors pan-genotypic regimens. Treatment programs prioritize high cure rates, simplified diagnosis, short duration, low price and supply reliability.
Daclatasvir remains relevant where:
- Genotype 3 treatment is a priority.
- Sofosbuvir-based regimens are available at low cost.
- National guidelines retain daclatasvir-based combinations.
- Public-health procurement values generic affordability.
- Alternative pan-genotypic regimens are unavailable or too expensive.
It is less competitive where Epclusa, Mavyret or generic equivalents are routinely available. Daclatasvir therefore occupies a secondary market position rather than a premium branded position.
What manufacturing and intellectual-property barriers remain?
Daclatasvir manufacturing requires control of chemical synthesis, impurity profiles, polymorphism, salt formation, tablet uniformity and stability. The dihydrochloride form must meet applicable pharmacopeial and regulatory specifications.
The remaining IP risks include:
- Active patents in individual jurisdictions.
- Patent-term adjustments or supplementary protection certificates.
- Process patents covering commercially efficient synthesis.
- Formulation claims that may affect a generic tablet.
- Data-exclusivity rules in countries with later registration.
- Trademark and packaging restrictions.
These barriers can delay registration but are unlikely to restore originator pricing. The most valuable capabilities are validated manufacturing, regulatory documentation and procurement access.
How does daclatasvir compare with Epclusa and Mavyret?
| Attribute |
Daclatasvir |
Epclusa |
Mavyret |
| Originator |
Bristol-Myers Squibb |
Gilead Sciences |
AbbVie |
| Core mechanism |
NS5A inhibitor |
NS5A plus nucleotide polymerase inhibitor |
NS3/4A protease plus NS5A inhibitor |
| Coverage |
Genotype-specific historical positioning |
Pan-genotypic |
Pan-genotypic |
| Current commercial status |
Mainly generic and public-health supply |
Major branded and generic competition |
Major branded and generic competition |
| Strategic strength |
Low price and established use |
Broad label and strong clinical positioning |
Short treatment options and broad coverage |
| U.S. growth outlook |
Minimal |
Mature but commercially relevant |
Mature but commercially relevant |
| Patent value |
Limited residual value |
More material due commercial scale |
More material due commercial scale |
Daclatasvir’s disadvantage is that it is a component of a treatment strategy rather than a complete pan-genotypic platform. Its advantage is cost, established regulatory experience and availability through access programs.
Key Takeaways
- Daclatasvir dihydrochloride is a mature HCV medicine with low current branded value.
- Daklinza’s commercial decline resulted from therapeutic substitution, price erosion and generic licensing.
- U.S. regulatory exclusivity largely expired around 2020, and the branded product was discontinued for commercial reasons.
- The drug has no biosimilar risk because it is a small molecule.
- Patent protection remains jurisdiction-specific but no longer provides a strong global commercial moat.
- Generic and public-health markets are the main sources of ongoing demand.
- Epclusa and Mavyret displaced daclatasvir in many markets through pan-genotypic coverage and simpler treatment positioning.
- Residual value depends on low-cost manufacturing, regulatory approvals, licensing territories and procurement contracts.
FAQs
Is daclatasvir dihydrochloride still commercially available?
Yes. It remains available in selected countries through generic manufacturers and public-health procurement channels, although availability and regulatory status vary by market.
Was Daklinza withdrawn because of safety concerns?
The U.S. commercial discontinuation was reported as a business decision rather than a safety-driven withdrawal of daclatasvir.
Does daclatasvir have biosimilar competition?
No. Daclatasvir is a chemically synthesized small molecule. Competition occurs through generic-drug pathways rather than biosimilar approval.
Can daclatasvir still be used for hepatitis C genotype 3?
It can remain clinically relevant in jurisdictions whose treatment guidelines and product registrations include daclatasvir-based combinations. Current treatment selection depends on local regulatory labeling and clinical guidance.
Is daclatasvir an attractive pharmaceutical licensing asset?
Its value is generally limited to selected emerging markets, public-health programs, generic supply arrangements and manufacturing partnerships. It is not a high-growth branded licensing asset.
References
-
Bristol-Myers Squibb. (2015). 2015 annual report. Bristol-Myers Squibb Company.
-
Bristol-Myers Squibb. (2016). 2016 annual report. Bristol-Myers Squibb Company.
-
European Medicines Agency. (2014). Daklinza: EPAR product information. European Medicines Agency.
-
U.S. Food and Drug Administration. (2015). Daklinza prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2020). Drugs@FDA: Daklinza application and product records. U.S. Department of Health and Human Services.
-
Medicines Patent Pool. (2017). Medicines Patent Pool and Bristol-Myers Squibb announce licensing agreement for daclatasvir. Medicines Patent Pool.
-
World Health Organization. (2022). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. World Health Organization.
-
World Health Organization. (2023). Global hepatitis report 2024. World Health Organization.
